Compare SPRO & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | CLAR |
|---|---|---|
| Founded | 2013 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 103.7M |
| IPO Year | 2017 | 1998 |
| Metric | SPRO | CLAR |
|---|---|---|
| Price | $2.24 | $2.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.81 |
| AVG Volume (30 Days) | ★ 261.3K | 233.5K |
| Earning Date | 03-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 3.75% |
| EPS Growth | ★ 111.81 | 11.68 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $66,802,000.00 | $228,000.00 |
| Revenue This Year | N/A | $5.27 |
| Revenue Next Year | N/A | $4.56 |
| P/E Ratio | $15.53 | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.51 | $2.59 |
| 52 Week High | $3.09 | $4.03 |
| Indicator | SPRO | CLAR |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 30.56 |
| Support Level | $2.15 | $2.59 |
| Resistance Level | $2.44 | $3.72 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 4.35 | 11.22 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.